Previous 10 | Next 10 |
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...
UroGen Pharma Ltd. (URGN) Q4 2021 Earnings Conference Call March 21, 2022, 10:00 AM ET Company Participants Vincent Perrone - Senior Director of Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer Jeff Bova - Chief Commercial Officer ...
UroGen Pharma press release (NASDAQ:URGN): Q4 GAAP EPS of -$1.27 misses by $0.07. Revenue of $16.17M (+102.9% Y/Y) misses by $0.32M. Guidance 2022: The Company anticipates full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million. The Company anticipates full y...
Jelmyto® net product revenue increased 42% over Q3 2021 with $16.2 million in Q4 2021; full-year net product revenue of $48.0 million in line with guidance Announced up to $100 million senior secured term loan facility with funds managed by Pharmakon Advisors, expected ...
Gainers: Hycroft Mining Holding (NASDAQ:HYMC) +111%. Enservco (NYSE:ENSV) +92%. Westport Fuel Systems (NASDAQ:WPRT) +54%. Nine Energy Service (NYSE:NINE) +38%. Voyager Therapeutics (NASDAQ:VYGR) +32%. PolyMet Mining (NYSE:PLM) +28%. Eco Wave Power Global AB (publ) (NASDAQ:WAVE) +26%. Ocean Po...
-- Initial Draw of $75 Million Available within 10 Business Days following Closing; Second Draw of $25 Million Available through the End of 2022 -- -- Reporting of Fourth Quarter and Full-Year Financial Results Rescheduled to March 21, 2022 -- UroGen Pharma Ltd...
Conference Call and Webcast Scheduled for Thursday, March 10, 2022, at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will ...
-- UGN-301 is an investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothe...
UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42 nd Annual Healthcare Confer...
--Investigator’s Retrospective Analysis Published in the Journal of Urology Provides Protocol for Antegrade Administration of Jelmyto, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer-- UroGen Pharma Ltd. (Nasdaq:...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...